Pyrazoles Patents (Class 514/406)
  • Patent number: 10655183
    Abstract: The present invention provides methods and kits a) for preventing and/or treating cancer (e.g., colorectal cancer, neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patient's whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and/or +316 of the ODC1 gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 genotype at the +263 and/or +316 positions, as a means to guide treatment selection.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: May 19, 2020
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF UNIVERSITY OF ARIZONA
    Inventors: Eugene Gerner, Patricia Thompson, Tracy Brooks, Jenaro Garcia-Huidobro
  • Patent number: 10654810
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: May 19, 2020
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 10647710
    Abstract: Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases related to herpes simplex viruses.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: May 12, 2020
    Assignee: Medshine Discovery Inc.
    Inventors: Haiying He, Zhigan Jiang, Weihua Shi, Jianhua Xia, Jian Li, Shuhui Chen
  • Patent number: 10640454
    Abstract: A process for preparation of 4-aminoindane derivatives of a first formula, salts and enantiomers thereof comprising the steps of: a) hydrogenating a 1,2-dihydroquinoline of a second formula to give a corresponding tetrahydroquinoline of a third formula; b) acylating the tetrahydroquinoline of the third formula with a carboxylic acid derivative of a fourth formula to obtain a corresponding acyl derivative compound of a fifth formula; c) rearranging the acyl derivative compound of the fifth formula under acidic conditions so as to give an acyl indane compound of a sixth formula; and d) hydrolysing the acyl group of the acyl indane compound of the sixth formula so as to obtain the 4-aminoindane derivatives of the first formula.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 5, 2020
    Assignee: STICHTING I-F PRODUCT COLLABORATION
    Inventors: Paolo Bellandi, Giampaolo Zanardi, Ravindra Vitthal Datar, Chockalingam Devarajan, Swamynathan Murali, Narayana Swamy
  • Patent number: 10632104
    Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: April 28, 2020
    Assignee: SABRE THERAPEUTICS LLC
    Inventors: Gretchen Bain, Jillian Frances Evans, John Howard Hutchinson, David Lonergan
  • Patent number: 10576088
    Abstract: It was found that finafloxacin has a high solubility in the presence of Tris. Such solubility is significantly higher than in the presence of other compounds typically used as buffers (e.g. phosphate buffer). The observed significant increase in solubility of finafloxacin in compositions comprising Tris is further advantageously accompanied by a long term stability of such solutions. Tris is therefore to be regarded as a specific tool to considerably enhance the solubility of finafloxacin in solutions. By preparing compositions comprising Tris it is possible to dissolve finafloxacin in such an amount therein that these compositions can effectively be used as parenteral compositions for the treatment of bacterial infections.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 3, 2020
    Assignee: MerLion Pharmaceuticals Pte. Ltd.
    Inventors: Carsten Fischer, Andreas Vente, Sven-Eric Wohlert
  • Patent number: 10570213
    Abstract: The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: February 25, 2020
    Assignee: Genentech, Inc.
    Inventors: Jeong Kim, Jeanne Cheung
  • Patent number: 10570086
    Abstract: The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: February 25, 2020
    Assignee: FMC Corporation
    Inventors: Narayana Swamy, Chokalingam Devarajan, Ravindra Vitthal Datar
  • Patent number: 10562858
    Abstract: A crystal form of 2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-methylphenol which is stable and has high purity for preservation, industrial manufacturing, and circulation, and process for providing the same by using a boron compound.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: February 18, 2020
    Assignee: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Toshiro Sasaki, Takahiro Imai, Kenichiro Mori, Makoto Ohyama, Takashi Watanabe
  • Patent number: 10543193
    Abstract: The present invention is directed to processes and intermediates useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea (Compound I), crystalline forms and solvate forms thereof; and compositions comprising 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea, crystalline forms and solvate forms thereof prepared by processes as described herein.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: January 28, 2020
    Assignee: ARENA PHARMACEUTICALS, INC.
    Inventors: Marlon Carlos, Weitong Dong, Mark Macias, Suzanne Michiko Sato, Lee Alani Selvey
  • Patent number: 10525144
    Abstract: The present invention provides compounds and a method for the targeted delivery of Mitochondrial Angiotensin Receptor Blockers (MARBs) to the Mitochondrial Angiotensin System (MAS) for the treatment of diseases caused by angiotensin-related mitochondrial dysfunction. The compounds include a mitochondrial targeting signal, a residue of a drug molecule, a functional moiety, and a scaffold moiety.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: January 7, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Honggang Cui, Peter M. Abadir, Jeremy D. Walston, Andrew G. Cheetham
  • Patent number: 10519137
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: December 31, 2019
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Steven John Woodhead, Michael Reader, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Timothy Pietro Suren Perera, Berthold Wroblowski, Alexandra Papanikos, Olivier Alexis Georges Querolle, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
  • Patent number: 10513497
    Abstract: Provided herein are improved processes for the preparation of a compound of Formula IX (AG-10). Also provided herein are pharmaceutically acceptable salts of Formula I and Formula Ib as well as crystalline types of Formula IX (AG-10). The processes described herein provide improved yields and efficiency, while the pharmaceutically acceptable salts and crystalline forms provide unexpected pharmacokinetic properties. Other features and aspects of the present disclosure will be apparent to a person of skill in the art upon reading the remainder of the specification.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: December 24, 2019
    Assignee: EIDOS THERAPEUTICS, INC.
    Inventors: Pooran Chand, Yogesh Kumar Gupta, Rakesh Kumar Kumawat, Mamoun Alhamadsheh, Robert Zamboni
  • Patent number: 10493089
    Abstract: A solid composition comprising sofosbuvir and at least one pharmaceutically acceptable matrix compound wherein at least 99 weight-% of the sofosbuvir comprised in the composition are present in amorphous form, at least 99 weight-% of the solid composition consist of the sofosbuvir and the at least one matrix compound, and wherein the solid composition contains the sofosbuvir in an amount of at least 55 weight-% based on the combined weight of the sofosbuvir and the at least one matrix compound.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: December 3, 2019
    Assignee: Sandoz AG
    Inventor: Nolwenn Martin
  • Patent number: 10471079
    Abstract: Combinations of certain analgesics with COX-II inhibitors, related pharmaceutical compositions, including advantageous galenical forms containing these combinations, and the use of such combinations in methods of treatment, in particular for the treatment of pain.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: November 12, 2019
    Assignee: GRUENENTHAL GMBH
    Inventors: Klaus Schiene, Guenter Haase, Babette-Yvonne Koegel, Elmar Friderichs, Ulrich Jahnel
  • Patent number: 10472328
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: November 12, 2019
    Assignee: TOLERO PHARMACEUTICALS, INC.
    Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
  • Patent number: 10449253
    Abstract: A method of delivering or sequestering anesthetic agents by adsorption of such agents by porous partially fluorinated compounds which display high weight adsorption capacities. Such compounds have a non-covalent organic framework with a central ring, such as hexa, tetra, tri or di substituted benzenes which may be substituted or unsubstituted with alternating electron poor and electron rich groups such as tetra-, tri-, or di-fluorobenzenes, oligocyanobenzenes, oligochlorobenzene, and benzene, pirydone, triazole, pyrazole, pyridine, and substituted benzenes so that the compound forms a porous supramolecular structure; and adsorbs the anesthetic agent within the pores of a the compound.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: October 22, 2019
    Assignee: UNIVERSITY OF HOUSTON SYSTEM
    Inventors: Ognjen Miljanic, Teng-Hao Chen, Watchareeya Kaveevivitchai
  • Patent number: 10415093
    Abstract: Methods for diagnosing or monitoring endometriosis in a mammal are provided. The methods include the steps of determining the expression levels of BDNF and its receptor, Ntrk2, in a biological sample from the mammal, and determining that the mammal has endometriosis when the BDNF and Ntrk2 expression levels in the sample are elevated.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: September 17, 2019
    Assignees: MCMASTER UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Warren Foster, Nicholas Leyland, Jocelyne Wessels, Sanjay Agarwal
  • Patent number: 10385051
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 20, 2019
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 10376527
    Abstract: The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: August 13, 2019
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Ankit Baheti, Bijay Kumar Padhi, Supritha Vakada, Rajeev Singh Raghuvanshi
  • Patent number: 10314841
    Abstract: The present invention provides compounds of Formula (II) for the treatment of cancer, rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: June 11, 2019
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Reinaldo Jones
  • Patent number: 10294207
    Abstract: Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: May 21, 2019
    Assignee: GREEN CROSS CORPORATION
    Inventors: Soongyu Choi, Kisoo Park, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Ickhwan Son, Sang-ho Ma, Kwang-Seop Song, Min Ju Kim, So Ok Park, Man-Young Cha, Mi-Soon Kim, Sang Mi Kang, Dong Hyuk Jang, Jangwon Hong
  • Patent number: 10287298
    Abstract: The present invention concerns compounds of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diasteroisomers thereof formula (I): wherein at least one of W, X and Y is selected from the group consisting of —NR1R2; —NR3—(CH2)n—NR4R5; —O—(CH2)n—NR4R5; —NR3—(CH2)n—N?R6R7R8; and —O—(CH2)n—N?R6R7R8 and Z is a functional group capable of chelating iron salts. The present invention also concerns the compounds of formula (I) for use as a drug, in particular, in the treatment of cancer and malaria.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: May 14, 2019
    Assignees: Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes
    Inventors: Maryam Mehrpour, Raphael Rodriguez, Antje Hienzsch, Mai Trang, Ahmed Hamai
  • Patent number: 10251853
    Abstract: The present invention relates to methods of treating fibromyalgia, by administering a therapeutically-effective combination of an antiviral component and a COX-2 inhibitor component. The invention is further related to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound famciclovir and a therapeutically-effective amount of the COX-2 inhibitor celecoxib. The invention is also related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of famciclovir and celecoxib.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: April 9, 2019
    Assignee: INNOVATIVE MED CONCEPTS, LLC
    Inventor: William L. Pridgen
  • Patent number: 10214492
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: February 26, 2019
    Assignee: Vettore, LLC
    Inventors: Kenneth Mark Parnell, John McCall, Donna Romero
  • Patent number: 10172959
    Abstract: A delivery system for active agents, and methods of making and using the systems, are provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: January 8, 2019
    Inventor: Mamoun M Alhamadsheh
  • Patent number: 10174034
    Abstract: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: January 8, 2019
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Kanthikiran V S Varansi, Gayatri Swaroop Merikapudi, Swaroop Kumar V. S. Vakkalanka
  • Patent number: 10165775
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes related thereto.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: January 1, 2019
    Assignee: Dow AgroSciences LLC
    Inventors: Noormohamed M. Niyaz, Negar Garizi, Yu Zhang, Tony K. Trullinger, Ricky Hunter, Ann M. Buysse, Asako Kubota, Paul R. LePlae, Jr., Daniel I. Knueppel, Christian T. Lowe, Dan Pernich, David A. Demeter, Timothy C. Johnson
  • Patent number: 10149473
    Abstract: New aminoindanes amides are described, having general formula (I) the relative phytosanitary compositions and their use for the control of phytopathogenic fungi.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: December 11, 2018
    Assignee: STICHTING I-F PRODUCT COLLABORATION
    Inventors: Isabella Venturini, Matteo Santino Vazzola, Entela Sinani, Franco Pellacini, Lucio Filippini
  • Patent number: 10130095
    Abstract: The present invention relates to novel compositions comprising certain pyrazolecarboxylic acid alkoxyamides according to formula (I) in combination with certain fungicides, to a process for preparing these compositions and to the use thereof as biologically active compositions, especially for the control of harmful microorganisms in plants and in the protection of materials and as plant growth regulators.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: November 20, 2018
    Assignee: BASF AGRO B.V.
    Inventors: Pierre-Yves Coqueron, Ulrike Wachendorff-Neumann, Sebastian Hoffmann, Philippe Desbordes, Pierre Cristau, Peter Dahmen
  • Patent number: 10117935
    Abstract: A method of delivering or sequestering anesthetic agents by adsorption of such agents by porous partially fluorinated compounds which display high weight adsorption capacities.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: November 6, 2018
    Assignee: UNIVERSITY OF HOUSTON SYSTEM
    Inventors: Ognjen Miljanic, Teng-Hao Chen, Watchareeya Kaveevivitchai
  • Patent number: 10071075
    Abstract: The present invention is directed to processes and intermediates useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea (Compound I), crystalline forms and solvate forms thereof; and compositions comprising 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea, crystalline forms and solvate forms thereof prepared by processes as described herein.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: September 11, 2018
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Marlon Carlos, Weitong Dong, Mark Macias, Suzanne Michiko Sato, Lee Alani Selvey
  • Patent number: 10067132
    Abstract: A diagnostic method for determining prognosis of a myocardial infarcted patient, wherein the amounts of FXIII protein are determined on the day of myocardial infarction (t0) and at least on the following three days (t1 to t3), wherein a lowering of FXIII amount on any one of t0 to t3 below a threshold value is indicative of an increased risk of poor prognosis.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: September 4, 2018
    Inventor: Donato Gemmati
  • Patent number: 10047055
    Abstract: Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: August 14, 2018
    Assignee: Ralexar Therapeutics, Inc.
    Inventor: Raju Mohan
  • Patent number: 10034846
    Abstract: The present invention relates to methods of treating fibromyalgia, by administering a therapeutically-effective combination of an antiviral component and a COX-2 inhibitor component. The invention is further related to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound famciclovir and a therapeutically-effective amount of the COX-2 inhibitor celecoxib. The invention is also related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of famciclovir and celecoxib.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: July 31, 2018
    Assignee: INNOVATIVE MED CONCEPTS, LLC
    Inventor: William L. Pridgen
  • Patent number: 10034860
    Abstract: Described herein are methods of treating locally advanced or metastatic estrogen receptor positive breast cancer.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: July 31, 2018
    Assignee: Genentech, Inc.
    Inventors: Edna Chow Maneval, Boa Tran H. Troung, Isan Chen, Jeffrey H. Hager, Debasish F. Roychowdhury
  • Patent number: 10022355
    Abstract: The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor and their uses for the treatment of REM sleep behavior disorder.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: July 17, 2018
    Assignee: Axovant Sciences GmbH
    Inventors: Lawrence Tim Friedhoff, Shankar Ramaswamy, Yandong Wen
  • Patent number: 9974771
    Abstract: Compositions and methods for reducing the level of prions in a prion-infected cells or host by exposing prion infected cells, tissues and organs to AR-12 and the AR-12 analog AR-14 to reduce the prion level by at least about 90%.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: May 22, 2018
    Assignees: OHIO STATE INNOVATION FOUNDATION, UTI LIMITED PARTNERSHIP
    Inventors: Hermann M. Schaetzl, Basant Abdulrahman, Sabine Gilch, Alexander Zukiwski, Stefan Proniuk
  • Patent number: 9961897
    Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein Q1, Q2, X, R1, R1a and R2 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: May 8, 2018
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Andrew Edmund Taggi, James Francis Bereznak
  • Patent number: 9951023
    Abstract: A method for the preparation of compounds of formula (I), for example, N-methyl-3-difluoromethyl-5-fluorpyrazole aldehyde, starting from compounds of formula (II), for example, N-methyl-3-haloalkyl-5 chloropyrazole aldehyde, comprising simultaneous fluorination (one step process) of haloalkyl group in position 3 and replacing haloatom in position 5 by fluorine.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: April 24, 2018
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Norbert Lui, Sergii Pazenok
  • Patent number: 9949990
    Abstract: The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: April 24, 2018
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Ankit Baheti, Bijay Kumar Padhi, Supritha Vakada, Rajeev Singh Raghuvanshi
  • Patent number: 9907806
    Abstract: The invention relates to pharmaceutical compositions for emergency contraception, to the use of levonorgestrel in combination with COX inhibitors for the preparation of pharmaceutical compositions for the stated purpose, and to a method for preparing these pharmaceutical compositions.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: March 6, 2018
    Assignee: BAYER INTELLECTUAL PROPERTY, GmbH
    Inventors: Bernhard Lindenthal, Rolf Schürmann, Sascha General
  • Patent number: 9896476
    Abstract: The glycyrrhetic acid derivatives can include: The glycyrrhetic acid derivatives can be used to treat inflammation and/or ulcers.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: February 20, 2018
    Assignee: KING SAUD UNIVERSITY
    Inventors: Abd El-Galil E. Amr, Mohamed A. Al-Omar, Nagy Mahmoud Hassan Khalifa
  • Patent number: 9889145
    Abstract: Methods to treat infectious diseases are disclosed herein. Some embodiments of the invention include administration of one or more COX inhibitors (e.g., COX-1 or COX-2 inhibitors) to treat infectious diseases. Other embodiments of the invention include administration of one or more COX inhibitors (e.g., COX-1 or COX-2 inhibitors) and administration of one or more antibiotics to treat infectious diseases.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: February 13, 2018
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Lisa Ann Morici, Saja Asakrah
  • Patent number: 9878985
    Abstract: The present invention relates to novel benzocyclobutane(thio) carboxamides, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: January 30, 2018
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Christophe Dubost, Ulrike Wachendorff-Neumann, Philipp Winter, Stephane Brunet, Jean-Pierre Vors, Cyril Montagne
  • Patent number: 9844221
    Abstract: The present invention relates to methods for controlling apple scab caused by Venturia inaequalis comprising spraying the bark of an apple tree with an effective amount of 3-(difluoromethyl)-1-methyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydroinden-4-yl]pyrazole-4-carboxamide and a surfactant.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: December 19, 2017
    Assignee: VALENT U.S.A. CORPORATION
    Inventor: Billy R. Corbin, Jr.
  • Patent number: 9833433
    Abstract: Embodiments of the present disclosure provide for compositions including an antimicrobial agent, pharmaceutical compositions including the composition or pharmaceutical composition, methods of treating a condition or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: December 5, 2017
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Chu Chen, Jian Zhang
  • Patent number: 9820969
    Abstract: This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: November 21, 2017
    Assignee: TRANSLATUM MEDICUS INC.
    Inventor: Shelley Romayne Boyd
  • Patent number: 9801856
    Abstract: The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improvise sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: October 31, 2017
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Lee Alani Selvey, Marlon Carlos, Paul Maffuid, Yun Shan, William L. Betts, III, Deam Windate Given, III, Ryan M. Hart, Zezhi Jesse Shao
  • Patent number: 9783503
    Abstract: Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the estrogen receptor modulator (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl) phenyl)acrylic acid. Also described are pharmaceutical compositions suitable for administration to a mammal that include the estrogen receptor modulator, and methods of using the estrogen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with estrogen receptor activity.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: October 10, 2017
    Assignee: GENENTECH, INC.
    Inventors: Nicholas D. Smith, Mark R. Herbert